935-P: Personality Traits and Glycemic Control in Type 1 Diabetic Patients with Different Insulin Therapies

Le résumé fourni par la source

Introduction and Objective: Glycemic variability is becoming increasingly important in evaluating effectiveness of treatment in patients with type 1 diabetes. Personality traits may impact daily therapeutic decisions, potentially affecting quality of glycemic control. This study aimed to explore potential relationship between personality traits and glycemic control, and to examine differences across various insulin therapies. Methods: Cross-sectional observational study, 130 type 1 diabetic patients (68 females, 62 males, 43.77±12.81 years, BMI 24.95±4.57 kg/m2, disease duration 23.23±12.39 years, HbA1c 7.04±0.92%), divided in three groups: 1. Multiple daily injections (MDI, n=45); 2. Traditional pumps (TP, n=35); 3. Advanced hybrid closed-loop systems (AHCL, n=50). Personality was assessed through the Personality Inventory for DSM-V questionnaire. Kruskal-Wallis test for independent samples was used to compare continuous variables among three groups. Associations between pairs of variables were analyzed using Spearman’s correlation. Results: AHCL group showed higher emotional lability (p=0.042), perseveration (p=0.005), separation insecurity (p=0.007) and distractibility (p=0.021) than MDI and TP group. The pathological trait of emotional lability (above the 75th percentile) was more frequently present in the AHCL (32%, p=0.029) than MDI and TP group. This trait was associated with an increase in TAR>180 (p=0.035) and GMI (p=0.025), a decrease in TBR<70 (p=0.014). However, glycemic control and metrics were significantly better in the AHCL than MDI and TP group (HbA1c, p=0.03; GRI, p<0.001; TIR, p=0.004; TAR>180, p=0.05; TBR<70, p=0.018, TAR>250, p=0.041; CV, p=0.012; SD, p=0.01). Conclusion: AHCL systems may help mitigating the impact of problematic personality traits, that could interfere achieving an optimal glycemic control. Disclosure E. Resmini: None. A.V. Cornaghi: None. V. Turra: None. E. Zarra: None. E. Cimino: Speaker's Bureau; roche, Abbott. M. Sandri: None. M. Migazzi: None. G. Massari: None. B. Pasquino: None. C. Mascadri: None. S. Madaschi: None. A. Girelli: Consultant; Abbott Diagnostics, Sanofi, Roche Diabetes Care.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.